Adaptive Biotechnologies Financial Statements (ADPT)
|
|
|
|
Report date
|
|
|
15.02.2022 |
14.02.2023 |
29.02.2024 |
03.03.2025 |
26.02.2026 |
|
05.05.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
154.3 |
185.3 |
170.3 |
179.0 |
277.0 |
|
295.4 |
|
Operating Income, bln rub |
|
|
-209.0 |
-200.2 |
-227.0 |
-162.5 |
-57.1 |
|
-46.7 |
|
EBITDA, bln rub |
? |
|
-193.3 |
-175.2 |
-189.3 |
-128.8 |
-29.8 |
|
-22.0 |
|
Net profit, bln rub |
? |
|
-207.3 |
-200.2 |
-225.3 |
-159.5 |
-59.5 |
|
-49.7 |
|
|
OCF, bln rub |
? |
|
-192.7 |
-183.9 |
-156.3 |
-95.2 |
-46.0 |
|
-27.0 |
|
CAPEX, bln rub |
? |
|
61.7 |
16.3 |
10.7 |
3.66 |
2.96 |
|
2.50 |
|
FCF, bln rub |
? |
|
-254.5 |
-200.3 |
-167.0 |
-98.9 |
-48.9 |
|
-29.5 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
|
|
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
314.0 |
327.6 |
321.8 |
269.4 |
262.7 |
|
269.0 |
|
Cost of production, bln rub |
|
|
49.3 |
57.9 |
75.6 |
72.1 |
71.4 |
|
73.1 |
|
R&D, bln rub |
|
|
142.3 |
141.8 |
122.1 |
103.0 |
93.8 |
|
93.2 |
|
Interest expenses, bln rub |
|
|
0.000 |
4.24 |
13.8 |
11.6 |
11.8 |
|
11.8 |
|
|
Assets, bln rub |
|
|
923.3 |
856.6 |
661.1 |
539.4 |
512.7 |
|
505.9 |
|
Net Assets, bln rub |
? |
|
604.0 |
464.2 |
308.4 |
202.7 |
218.8 |
|
216.3 |
|
Debt, bln rub |
|
|
111.7 |
108.0 |
98.8 |
89.4 |
280.6 |
|
208.2 |
|
Cash, bln rub |
|
|
353.1 |
498.2 |
346.4 |
222.3 |
227.0 |
|
218.3 |
|
Net debt, bln rub |
|
|
-241.3 |
-390.2 |
-247.6 |
-132.9 |
53.6 |
|
-10.2 |
|
|
Ordinary share price, rub |
|
|
28.1 |
|
|
6.00 |
16.2 |
|
17.2 |
|
Number of ordinary shares, mln |
|
|
140.4 |
142.5 |
144.4 |
147.1 |
151.7 |
|
155.5 |
|
|
Market cap, bln rub |
|
|
3 938 |
0 |
0 |
883 |
2 464 |
|
2 678 |
|
EV, bln rub |
? |
|
3 697 |
-390 |
-248 |
750 |
2 518 |
|
2 668 |
|
Book value, bln rub |
|
|
476 |
338 |
184 |
80 |
98 |
|
96 |
|
|
EPS, rub |
? |
|
-1.48 |
-1.40 |
-1.56 |
-1.08 |
-0.39 |
|
-0.32 |
|
FCF/share, rub |
|
|
-1.81 |
-1.41 |
-1.16 |
-0.67 |
-0.32 |
|
-0.19 |
|
BV/share, rub |
|
|
3.39 |
2.37 |
1.28 |
0.55 |
0.65 |
|
0.62 |
|
|
EBITDA margin, % |
? |
|
-125.3% |
-94.6% |
-111.2% |
-71.9% |
-10.8% |
|
-7.46% |
|
Net margin, % |
? |
|
-134.3% |
-108.0% |
-132.3% |
-89.1% |
-21.5% |
|
-16.8% |
|
FCF yield, % |
? |
|
-6.46% |
|
|
-11.2% |
-1.99% |
|
-1.10% |
|
ROE, % |
? |
|
-34.3% |
-43.1% |
-73.0% |
-78.7% |
-27.2% |
|
-23.0% |
|
ROA, % |
? |
|
-22.4% |
-23.4% |
-34.1% |
-29.6% |
-11.6% |
|
-9.82% |
|
|
P/E |
? |
|
-19.0 |
0.00 |
0.00 |
-5.53 |
-41.4 |
|
-53.9 |
|
P/FCF |
|
|
-15.5 |
0.00 |
0.00 |
-8.93 |
-50.3 |
|
-90.7 |
|
P/S |
? |
|
25.5 |
0.00 |
0.00 |
4.93 |
8.90 |
|
9.07 |
|
P/BV |
? |
|
8.27 |
0.00 |
0.00 |
11.0 |
25.1 |
|
27.9 |
|
EV/EBITDA |
? |
|
-19.1 |
2.23 |
1.31 |
-5.82 |
-84.4 |
|
-121.1 |
|
Debt/EBITDA |
|
|
1.25 |
2.23 |
1.31 |
1.03 |
-1.80 |
|
0.46 |
|
|
R&D/CAPEX, % |
|
|
230.5% |
867.1% |
1 142% |
2 810% |
3 169% |
|
3 734% |
|
|
CAPEX/Revenue, % |
|
|
40.0% |
8.82% |
6.28% |
2.05% |
1.07% |
|
0.84% |
|
| Adaptive Biotechnologies shareholders |
